EAU 2013 - Programme Book - YouMed

More documents

Recommendations

Info

Monday 973 Percutaneous nephrolithotomy without hydrodistension M. Villalobos-Gollas, E. Cruz-Nuricumbo, L. Gómez-De-Regil (Merida, Mexico) 974 Is standard percutaneous nephrolithotomy still standard? Comparison of surgical outcomes between tubeless and standard percutaneous nephrolithotomy J.K. Oh, C.H. Kim, S.C. Lee, K.T. Kim, T.B. Kim, K.H. Kim, S.J. Yoon, H. Jung (Incheon, South Korea) 292 Programme Book
Monday, 18 March - EAU Programme Abstract Session 14.00 - 15.30 Renal tumours: Drug related basic research Red Hall 2 - Level N1 Poster Session 80 Chairs: F. Birkhäuser, Berne (CH) T. Klatte, Vienna (AT) Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 4 minutes in length, followed by 2 minutes for discussion. 975 Pre-clinical trial of a new dual mTOR inhibitor: INK128 for renal cell carcinoma A. Ingels, A. Thong, M. Saar, M.P. Valta, R. Nolley, J. Santos, H. Zhao, D. Peehl (Stanford, United States of America) 976 Panobinostat and bortezomib inhibit renal cancer growth in vitro and in vivo by inducing endoplasmic reticulum stress and ubiquitinated protein accumulation synergistically A. Sato, T. Asano, K. Ito, T. Asano (Tokorozawa, Japan) 977 Ritonavir, a potent inhibitor of CYP3A4, enhances the anticancer effects of panobinostat in renal cancer cells in vitro and in vivo A. Sato, T. Asano, K. Ito, T. Asano (Tokorozawa, Japan) 978 A novel therapeutic approach for renal cell cancer cells using orally available phenylpiperazine derivative naftopidil Y. Iwamoto, H. Kanda, M. Kato, T. Sasaki, K. Ishii, K. Arima, T. Shiraishi, Y. Sugimura (Tsu, Japan) 979 Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1 T. Kijima, F. Koga, Y. Fujii, S. Yoshida, M. Tatokoro, K. Kihara (Tokyo, Japan) * 980 Optimization of Lutetium-177-G250 radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model C.H.J. Muselaers, O.C. Boerman, D.L. Bos, W.J.G. Oyen, E. Oosterwijk, P.F.A. Mulders (Nijmegen, The Netherlands) 981 Predictive value of angiogenic biomarkers in tuberous sclerosis complex (TSC) patients with renal angiomyolipoma (AML) K. Budde, J.C. Kingswood, T. Brechenmacher, K. Stein, D. Chen, J.J. Bissler (Berlin, Germany; Brighton, United Kingdom; Rueil-Malmaison, France; East Hanover, New Jersey, Cincinnati, Ohio, United States of America) 982 Sorafenib enhances the anti-tumor effect of anti-CTLA-4 antibody to kidney cancer T. Motoshima, Y. Komohara, Y. Kawano, Y. Wada, M. Eto (Kumamoto, Japan) 983 Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumor cell proliferation H. Miyake, I. Sakai, M. Fujisawa (Kobe, Japan) * 984 Potential predictive markers for a response to sunitinib and their association with survival of patients with metastatic renal cell carcinoma J. Dornbusch, M. Meinhardt, K. Erdmann, A. Zacharis, S. Zastrow, S. Füssel, M.P. Wirth (Dresden, Germany) EAU Milan 2013 293 Monday
Page 1 and 2:
It’s easy to save money on your f
Page 3 and 4:
Welcome to Milan by the EAU Secreta
Page 5 and 6:
EAU Member Benefits at EAU 2013! EA
Page 7 and 8:
Prize for the Best Scientific Paper
Page 9 and 10:
Acknowledgement of Abstract reviewe
Page 11 and 12:
J. Rubio Briones, Valencia (ES) A.
Page 13 and 14:
Connection Level S0 - N1 Connection
Page 15 and 16:
Programme Friday, 15 March eURO Aud
Page 17 and 18:
Blue Hall 1-2 Yellow Hall 1-2-3 Gre
Page 19 and 20:
Yellow Hall 1-2-3 Green Hall 1 Gree
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
EAUN Programme Overview, 16-18 Marc
Page 31 and 32:
HALL - SOUTH LEVEL M.A.S. EPLAPROME
Page 33 and 34:
ICAL SYSTEMS ASPIDE MÉDICAL ALLERG
Page 35 and 36:
E EAU BOOTH .......................
Page 37:
Q QUANTA SYSTEM SPA ...............
Page 40 and 41:
General General information Badge T
Page 42 and 43:
General General information EAU Boo
Page 44 and 45:
General General information • Gai
Page 46 and 47:
General Speaker guidelines Speaker
Page 48 and 49:
General EU-ACME Programme The EU-AC
Page 50 and 51:
General Congress hotels Best Wester
Page 52 and 53:
General Congress hotels Regency Mil
Page 54 and 55:
Friday 12.00 - 12.15 Management of
Page 56 and 57:
Friday Friday, 15 March - EAU Progr
Page 58 and 59:
Friday 12.45 - 12.55 Clinical cases
Page 60 and 61:
Friday 12.05 - 12.30 Words of Wisdo
Page 62 and 63:
Friday 12.20 - 12.35 Posterior uret
Page 64 and 65:
Friday 12.55 - 13.00 Closing remark
Page 66 and 67:
Friday 15.05 - 15.20 Molecular mech
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Friday Friday, 15 March - Sponsored
Page 76 and 77:
Saturday Saturday, 16 March - EAU P
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Saturday 86 Programme Book 60 Genom
Page 88 and 89:
Saturday 88 Programme Book 72 Compe
Page 90 and 91:
Saturday 90 Programme Book 82 Seque
Page 92 and 93:
Saturday * 96 Partial nephrectomy f
Page 94 and 95:
Saturday 11.50 - 12.05 Debate: Acad
Page 96 and 97:
Saturday Saturday, 16 March - EAU S
Page 98 and 99:
Saturday 16.55 - 17.05 ICG-assisted
Page 100 and 101:
Saturday 11.30 - 11.50 Male inconti
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Saturday 131 Mid-term analysis (6 m
Page 120 and 121:
Saturday 141 Pre-biopsy magnetic re
Page 122 and 123:
Saturday 154 MAC387 positive tumor-
Page 124 and 125:
Saturday 169 Spectrum and antibioti
Page 126 and 127:
Saturday 177 Analysis of Fuhrman gr
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Saturday Saturday, 16 March - Spons
Page 144 and 145:
Sunday 144 Programme Book the evide
Page 146 and 147:
Sunday Sunday, 17 March - EAU Progr
Page 148 and 149:
Sunday * 274 Prostate cancer active
Page 150 and 151:
Sunday 283 Incidence and prognostic
Page 152 and 153:
Sunday 299 Perioperative, functiona
Page 154 and 155:
Sunday 309 Withdrawn 310 Sacral neu
Page 156 and 157:
Sunday 322 Accuracy in measuring re
Page 158 and 159:
Sunday 333 Adrenomedullin and angio
Page 160 and 161:
Sunday 345 Diffusion weigthed MRI o
Page 162 and 163:
Sunday 162 Programme Book Aims and
Page 164 and 165:
Page 166 and 167:
Sunday 11.45 - 12.00 Abstract prese
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Sunday 360 Choline PET-CT and diffu
Page 178 and 179:
Sunday 372 Ultrasonography and cyto
Page 180 and 181:
Sunday 384 Comparative urological c
Page 182 and 183:
Sunday 397 Early results of the pil
Page 184 and 185:
Sunday 410 Efficacy and safety of t
Page 186 and 187:
Sunday 424 Correlation of severity
Page 188 and 189:
Sunday 436 Predicting urinary stone
Page 190 and 191:
Sunday 448 Quotient of non-micturit
Page 192 and 193:
Sunday 462 Patient-reported satisfa
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Sunday 589 Limitation of the curren
Page 216 and 217:
Sunday 601 Role of conventional cyt
Page 218 and 219:
Sunday 611 Change in renal function
Page 220 and 221:
Sunday 625 Predictors of admission
Page 222 and 223:
Sunday 636 Thulium VapoEnucleation
Page 224 and 225:
Sunday 650 Comparative analysis of
Page 226 and 227:
Sunday 661 Treatment response in st
Page 228 and 229:
Sunday * 673 Urinary levels of neur
Page 230 and 231:
Sunday 682 When to start antiresorp
Page 233 and 234:
Monday, 18 March - EAU Programme Pl
Page 235 and 236:
• what the potential is for combi
Page 237 and 238:
Monday, 18 March - EAU Programme Ab
Page 239 and 240:
Monday, 18 March - EAU Programme Ab
Page 241 and 242: Monday, 18 March - EAU Programme Ab
Page 255 and 256: Monday, 18 March - EAU Programme Th
Page 257 and 258: 325 Repair of erectile dysfunction
Page 273 and 274: 856 Reducing the number of prostate
Page 275 and 276: 871 Bladder wall substitution with
Page 277 and 278: 885 Intracorporeal cooling and extr
Page 279 and 280: * 898 Mini-Arc for the treatment of
Page 281 and 282: 908 The alteration of matrix metall
Page 291: Monday, 18 March - EAU Programme Ab
Page 299 and 300: Monday, 18 March - EAU Programme Sp
Page 313 and 314: 1095 Nocturia improvement in the Co
Page 315 and 316: 1106 The German mRCC registry - aim
Page 317 and 318: Tuesday, 19 March - EAU Programme P
Page 319: Patient perspective T. Hudson, Dubl
Page 322 and 323: ESU Courses ESU Courses, 16 March 3
Page 330 and 331: ESU Courses 330 Programme Book All
Page 332 and 333: ESU Courses 332 Programme Book Clas
Page 336 and 337: ESU Courses 336 Programme Book - Th
Page 342 and 343:
ESU Courses ESU Courses, 17 March 3
Page 344 and 345:
ESU Courses 344 Programme Book expe
Page 346 and 347:
ESU Courses 346 Programme Book Regi
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
ESU Courses 362 Programme Book Regi
Page 364 and 365:
ESU Courses 364 Programme Book Thus
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
ESU Hands-on ESU Hands-on, 16 March
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
Page 384 and 385:
Page 386 and 387:
Page 388 and 389:
Page 390 and 391:
Page 392 and 393:
Page 394 and 395:
Page 396 and 397:
Webcasts of sponsored sessions have
Page 398 and 399:
Sponsored Sessions Friday, 15 March
Page 400 and 401:
Sponsored Sessions Friday, 15 March
Page 402 and 403:
Sponsored Sessions Saturday, 16 Mar
Page 404 and 405:
Page 406 and 407:
Page 408 and 409:
Page 410 and 411:
Sponsored Sessions Sunday, 17 March
Page 412 and 413:
Page 414 and 415:
Page 416 and 417:
Page 418 and 419:
Sponsored Sessions Monday, 18 March
Page 420 and 421:
Sponsored Sessions Monday, 18 March
Page 422 and 423:
A new vision to understanding medic
Page 424 and 425:
About EAU EAU Offices EAU Board Exe
Page 426 and 427:
About EAU Additional EAU Foundation
Page 428 and 429:
Join the European Association of Ur
Page 430 and 431:
Indices Abstract authors Altinkilic
Page 432 and 433:
Indices Abstract authors Beukers W.
Page 434 and 435:
Indices Abstract authors Castellano
Page 436 and 437:
Indices Abstract authors Dalton S.O
Page 438 and 439:
Indices Abstract authors Elsaesser
Page 440 and 441:
Indices Abstract authors Garcia Gar
Page 442 and 443:
Indices Abstract authors Hamamoto S
Page 444 and 445:
Indices Abstract authors Ilyas R. 3
Page 446 and 447:
Indices Abstract authors Kim J.H. 3
Page 448 and 449:
Indices Abstract authors Lee J-L. 1
Page 450 and 451:
Indices Abstract authors Martin X.
Page 452 and 453:
Indices Abstract authors Müller A.
Page 454 and 455:
Indices Abstract authors Pacik D. 6
Page 456 and 457:
Indices Abstract authors Rajan P. 9
Page 458 and 459:
Indices Abstract authors Samaraseke
Page 460 and 461:
Indices Abstract authors Sinescu I.
Page 462 and 463:
Indices Abstract authors Tennstedt
Page 464 and 465:
Indices Abstract authors Von Schön
Page 466 and 467:
Indices Abstract authors Zattoni F.
Page 468 and 469:
Indices Abstract sorted by Topic 69
Page 470 and 471:
Indices Sessions sorted by Topic An
Page 472 and 473:
Indices List of Speakers (not abstr
Page 474 and 475:
Indices List of Speakers (not abstr
show all

EAU 2013 - Programme Book - YouMed

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?